---
title: 'Methotrexate Versus Mycophenolate Mofetil Prophylaxis inÂ Allogeneic Hematopoietic
  Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis
  on Behalf of the Chronic Malignancies Working Party of the EBMT'
date: '2024-11-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39605194/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241128174912&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic
  hematopoietic cell transplantation (allo-HCT) frequently encompass a combination
  of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate
  mofetil (MMF). The aim of this retrospective, EBMT registry-based study was to determine
  outcome differences for chronic myeloid malignancies and secondary acute myeloid
  leukemia (sAML) between MTX- and MMF-based prophylaxis regimens while taking ...
disable_comments: true
---
Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) frequently encompass a combination of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF). The aim of this retrospective, EBMT registry-based study was to determine outcome differences for chronic myeloid malignancies and secondary acute myeloid leukemia (sAML) between MTX- and MMF-based prophylaxis regimens while taking ...